Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
October 29, 2019 at 04:02 am EDT
Share
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 1,691.027 million compared to CNY 1,594.829 million a year ago. Operating income was CNY 309.653 million compared to CNY 253.048 million a year ago. Net income was CNY 261.818 million compared to CNY 212.776 million a year ago. Basic earnings per share from continuing operations was CNY 0.449 compared to CNY 0.359 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
